Keytruda- Inlyta Treatment Combination Improves Outcomes in Renal Cell Caner

The pivotal Phase 3 KEYNOTE-426 clinical trial investigating Keytruda (pembrolizumab) anti-PD-1 therapy in combination with Inlyta (axitinib), a tyrosine kinase inhibitor (TKI) improved both overall survival (OS) and delayed the time to cancer progression compared to Sutent (sunitinib) when used in the first-line treatment of advanced or metastatic renal cell carcinoma (RCC).12/13/2018
Source: Kidney Cancer Association - Category: Urology & Nephrology Source Type: news